Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?

被引：0
|
作者：
Arulananda, Surein
John, Thomas
机构：
[1] Olivia Newton John Canc Res Inst, Canc Immunobiol Lab, Heidelberg, Vic, Australia
[2] Austin Hlth, Dept Med Oncol, Heidelberg, Vic, Australia
[3] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; OSIMERTINIB;
D O I：
10.1016/j.jtho.2019.10.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [1] Gefitinib Approved for EGFR-Mutated NSCLC
    不详
    [J]. CANCER DISCOVERY, 2015, 5 (09) : 896 - 896
  • [2] Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
    Noronha, Vanita
    Patil, Vijay Maruti
    Joshi, Amit
    Menon, Nandini
    Chougule, Anuradha
    Mahajan, Abhishek
    Janu, Amit
    Purandare, Nilendu
    Kumar, Rajiv
    More, Sucheta
    Goud, Supriya
    Kadam, Nandkumar
    Daware, Nilesh
    Bhattacharjee, Atanu
    Shah, Srushti
    Yadav, Akanksha
    Trivedi, Vaishakhi
    Behel, Vichitra
    Dutt, Amit
    Banavali, Shripad Dinanath
    Prabhash, Kumar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 124 - +
  • [3] A Phase III Study Comparing Gefitinib and Inserted Cisplatin plus Pemetrexed with Gefitinib for EGFR-Mutated Advanced Non-Squamous NSCLC
    Kanda, Shintaro
    Mizutani, Tomonori
    Shibata, Taro
    Niho, Seiji
    Kurata, Takayasu
    Nakamura, Shinichiro
    Yamamoto, Nobuyuki
    Ohe, Yuichiro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1085 - S1085
  • [4] Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
    Menon, N. S.
    Noronha, V.
    Chowdhury, O. Row
    Pawar, A. R.
    Patil, V. M.
    Singh, A. C.
    More, S.
    Goud, S.
    Yadav, A.
    Shah, M. J.
    Jobanputra, K. N.
    Shah, D. K.
    Prabhash, K.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1637 - S1637
  • [5] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 137 - 147
  • [6] QTWiST Analysis to Compare the Benefit of Gefitinib Versus Pemetrexed Platinum for Patients with EGFR Mutated NSCLC
    Patil, V.
    Noronha, V.
    Joshi, A.
    Goel, A.
    Talreja, V.
    Kapoor, A.
    Kumar, R.
    Mahajan, A.
    Janu, A.
    Prabhash, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2231 - S2232
  • [7] RELAYþ: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
    Nishio, Makoto
    Nishio, Kazuto
    Reck, Martin
    Garon, Edward B.
    Imamura, Fumio
    Kawaguchi, Tomoya
    Yamaguchi, Hiroyuki
    Ikeda, Satoshi
    Hirano, Katsuya
    Visseren-Grul, Carla
    Ceccarelli, Matteo
    Wijayawardana, Sameera R.
    Zimmermann, Annamaria
    Matsui, Tomok
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (04):
  • [8] Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
    Patil, Vijay Maruti
    Noronha, Vanita
    Joshi, Amit
    Choughule, Anuradha Bharat
    Bhattacharjee, Atanu
    Kumar, Rajiv
    Goud, Supriya
    More, Sucheta
    Ramaswamy, Anant
    Karpe, Ashay
    Pande, Nikhil
    Chandrasekharan, Arun
    Goel, Alok
    Talreja, Vikas
    Mahajan, Abhishek
    Janu, Amit
    Purandare, Nilendu
    Prabhash, Kumar
    [J]. ESMO OPEN, 2017, 2 (01)
  • [9] Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis
    Fan, Y.
    Wu, H.
    Chen, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
  • [10] Osimertinib also improves overall survival in EGFR-mutated NSCLC
    Lichert, Frank
    [J]. PNEUMOLOGIE, 2024, 78 (03): : 143 - 143
12345